These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 26569382

  • 21. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
    Wang-Bishop L, Chen Z, Gomaa A, Lockhart AC, Salaria S, Wang J, Lewis KB, Ecsedy J, Washington K, Beauchamp RD, El-Rifai W.
    Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
    [Abstract] [Full Text] [Related]

  • 22. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W.
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [Abstract] [Full Text] [Related]

  • 23. Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.
    Masselli E, Carubbi C, Gobbi G, Mirandola P, Galli D, Martini S, Bonomini S, Crugnola M, Craviotto L, Aversa F, Vitale M.
    Leukemia; 2015 Nov; 29(11):2192-201. PubMed ID: 26183534
    [Abstract] [Full Text] [Related]

  • 24. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH, Rajan R, Emadi A.
    Med Princ Pract; 2016 Nov; 25(6):501-509. PubMed ID: 27756071
    [Abstract] [Full Text] [Related]

  • 25. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A, Park SO, Wamsley HL, Gali M, Baskin R, Reinhard MK, Zhao ZJ, Bisht KS, Keserű GM, Cogle CR, Sayeski PP.
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
    Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL.
    Blood; 2010 Apr 08; 115(14):2919-27. PubMed ID: 20154217
    [Abstract] [Full Text] [Related]

  • 28. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
    Spangrude GJ, Lewandowski D, Martelli F, Marra M, Zingariello M, Sancillo L, Rana RA, Migliaccio AR.
    Stem Cells; 2016 Jan 08; 34(1):67-82. PubMed ID: 26439305
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
    Yang J, Ikezoe T, Nishioka C, Nobumoto A, Udaka K, Yokoyama A.
    Int J Cancer; 2013 Dec 01; 133(11):2706-19. PubMed ID: 23686525
    [Abstract] [Full Text] [Related]

  • 32. Differentiation therapy for murine myelofibrosis model with MLN8237 loaded low-density lipoproteins.
    He B, Wang C, Wang F, Tian L, Wang H, Fu C, Liu J, Xi C, Zhu C, Yang Q.
    J Control Release; 2023 Apr 01; 356():554-566. PubMed ID: 36924895
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Feb 01; 88(2):141-50. PubMed ID: 23349007
    [Abstract] [Full Text] [Related]

  • 35. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
    Yasuda S, Aoyama S, Yoshimoto R, Li H, Watanabe D, Akiyama H, Yamamoto K, Fujiwara T, Najima Y, Doki N, Sakaida E, Edahiro Y, Imai M, Araki M, Komatsu N, Miura O, Kawamata N.
    Int J Hematol; 2021 Oct 01; 114(4):424-440. PubMed ID: 34165774
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM, Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative.
    PLoS One; 2013 Oct 01; 8(1):e54826. PubMed ID: 23382981
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Aurka loss in CD19+ B cells promotes megakaryocytopoiesis via IL-6/STAT3 signaling-mediated thrombopoietin production.
    Chen X, Wang C, Sun N, Pan S, Li R, Li X, Zhao J, Tong H, Tang Y, Han J, Qiao J, Qiu H, Wang H, Yang J, Ikezoe T.
    Theranostics; 2021 Oct 01; 11(10):4655-4671. PubMed ID: 33754019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.